Annual CFF
$5.14 M
+$4.46 M+652.56%
December 31, 2023
Summary
- As of February 23, 2025, APRE annual cash flow from financing activities is $5.14 million, with the most recent change of +$4.46 million (+652.56%) on December 31, 2023.
- During the last 3 years, APRE annual CFF has risen by +$4.99 million (+3306.23%).
- APRE annual CFF is now -94.45% below its all-time high of $92.58 million, reached on December 31, 2019.
Performance
APRE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$1200.00
+$19.90 K+94.31%
September 30, 2024
Summary
- As of February 23, 2025, APRE quarterly cash flow from financing activities is -$1200.00, with the most recent change of +$19.90 thousand (+94.31%) on September 30, 2024.
- Over the past year, APRE quarterly CFF has stayed the same.
- APRE quarterly CFF is now -100.00% below its all-time high of $91.20 million, reached on December 31, 2019.
Performance
APRE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$14.69 M
-$1200.00-0.01%
September 30, 2024
Summary
- As of February 23, 2025, APRE TTM cash flow from financing activities is $14.69 million, with the most recent change of -$1200.00 (-0.01%) on September 30, 2024.
- Over the past year, APRE TTM CFF has stayed the same.
- APRE TTM CFF is now -84.13% below its all-time high of $92.58 million, reached on December 31, 2019.
Performance
APRE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
APRE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +652.6% | 0.0% | 0.0% |
| 3 y3 years | +3306.2% | 0.0% | 0.0% |
| 5 y5 years | -90.9% | 0.0% | 0.0% |
APRE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +652.6% | -100.0% | +94.3% | -0.1% | +2050.7% |
| 5 y | 5-year | -94.5% | +3306.2% | -100.0% | +94.3% | -84.1% | -100.0% |
| alltime | all time | -94.5% | -100.0% | -100.0% | +100.0% | -84.1% | -100.0% |
Aprea Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1200.00(-94.3%) | $14.69 M(-0.0%) |
| Jun 2024 | - | -$21.10 K(-100.1%) | $14.69 M(-0.1%) |
| Mar 2024 | - | $14.71 M(>+9900.0%) | $14.71 M(+186.2%) |
| Dec 2023 | $5.14 M(+652.6%) | $0.00(0.0%) | $5.14 M(-1.9%) |
| Sep 2023 | - | $0.00(0.0%) | $5.24 M(-10.0%) |
| Jun 2023 | - | $0.00(-100.0%) | $5.82 M(0.0%) |
| Mar 2023 | - | $5.14 M(+5118.3%) | $5.82 M(+752.7%) |
| Dec 2022 | $683.00 K(-60.9%) | $98.50 K(-83.1%) | $682.90 K(-69.6%) |
| Sep 2022 | - | $584.40 K(>+9900.0%) | $2.24 M(+28.5%) |
| Jun 2022 | - | $0.00(0.0%) | $1.75 M(0.0%) |
| Mar 2022 | - | $0.00(-100.0%) | $1.75 M(0.0%) |
| Dec 2021 | $1.75 M | $1.66 M(+1808.0%) | $1.75 M(+1908.0%) |
| Sep 2021 | - | $87.00 K(>+9900.0%) | $87.00 K(>+9900.0%) |
| Jun 2021 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $0.00(0.0%) | $121.40 K(-19.5%) |
| Dec 2020 | $150.90 K(-99.8%) | $0.00(0.0%) | $150.90 K(-99.8%) |
| Sep 2020 | - | $0.00(-100.0%) | $91.35 M(+4.1%) |
| Jun 2020 | - | $121.40 K(+311.5%) | $87.73 M(+0.6%) |
| Mar 2020 | - | $29.50 K(-100.0%) | $87.17 M(-5.8%) |
| Dec 2019 | $92.58 M(+64.2%) | $91.20 M(-2619.5%) | $92.58 M(+6622.0%) |
| Sep 2019 | - | -$3.62 M(+730.6%) | $1.38 M(-72.4%) |
| Jun 2019 | - | -$435.80 K(-108.0%) | $5.00 M(-8.0%) |
| Mar 2019 | - | $5.43 M | $5.43 M |
| Dec 2018 | $56.37 M(+141.5%) | - | - |
| Dec 2017 | $23.34 M(+1258.0%) | - | - |
| Jun 2008 | $1.72 M(+6.5%) | - | - |
| Jun 2007 | $1.61 M(-25.4%) | - | - |
| Jun 2006 | $2.16 M(>+9900.0%) | - | - |
| Dec 2004 | $0.00 | - | - |
FAQ
- What is Aprea Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aprea Therapeutics?
- What is Aprea Therapeutics annual CFF year-on-year change?
- What is Aprea Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aprea Therapeutics?
- What is Aprea Therapeutics quarterly CFF year-on-year change?
- What is Aprea Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aprea Therapeutics?
- What is Aprea Therapeutics TTM CFF year-on-year change?
What is Aprea Therapeutics annual cash flow from financing activities?
The current annual CFF of APRE is $5.14 M
What is the all time high annual CFF for Aprea Therapeutics?
Aprea Therapeutics all-time high annual cash flow from financing activities is $92.58 M
What is Aprea Therapeutics annual CFF year-on-year change?
Over the past year, APRE annual cash flow from financing activities has changed by +$4.46 M (+652.56%)
What is Aprea Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of APRE is -$1200.00
What is the all time high quarterly CFF for Aprea Therapeutics?
Aprea Therapeutics all-time high quarterly cash flow from financing activities is $91.20 M
What is Aprea Therapeutics quarterly CFF year-on-year change?
Over the past year, APRE quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Aprea Therapeutics TTM cash flow from financing activities?
The current TTM CFF of APRE is $14.69 M
What is the all time high TTM CFF for Aprea Therapeutics?
Aprea Therapeutics all-time high TTM cash flow from financing activities is $92.58 M
What is Aprea Therapeutics TTM CFF year-on-year change?
Over the past year, APRE TTM cash flow from financing activities has changed by $0.00 (0.00%)